X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Glenmark Pharma with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GLENMARK PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-16
ADCOCK INGRAM
Jun-14
GLENMARK PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs1,262350-   
Low Rs672253-   
Sales per share (Unadj.) Rs270.6104.2-  
Earnings per share (Unadj.) Rs24.9-26.2-  
Cash flow per share (Unadj.) Rs34.4-21.8-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs151.381.8-  
Shares outstanding (eoy) m282.16168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.62.9 123.5%   
Avg P/E ratio x38.9-11.5 -338.4%  
P/CF ratio (eoy) x28.1-13.9 -202.7%  
Price / Book Value ratio x6.43.7 173.3%  
Dividend payout %8.00-   
Avg Mkt Cap Rs m272,77850,869 536.2%   
No. of employees `00010.04.3 233.5%   
Total wages/salary Rs m13,7823,193 431.7%   
Avg. sales/employee Rs Th7,614.94,095.3 185.9%   
Avg. wages/employee Rs Th1,374.8743.7 184.9%   
Avg. net profit/employee Rs Th700.2-1,031.9 -67.8%   
INCOME DATA
Net Sales Rs m76,34017,581 434.2%  
Other income Rs m356123 289.3%   
Total revenues Rs m76,69617,704 433.2%   
Gross profit Rs m14,172-3,047 -465.1%  
Depreciation Rs m2,691759 354.7%   
Interest Rs m1,789476 375.6%   
Profit before tax Rs m10,048-4,159 -241.6%   
Minority Interest Rs m0-12 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,028260 1,165.4%   
Profit after tax Rs m7,019-4,430 -158.4%  
Gross profit margin %18.6-17.3 -107.1%  
Effective tax rate %30.1-6.2 -482.4%   
Net profit margin %9.2-25.2 -36.5%  
BALANCE SHEET DATA
Current assets Rs m59,09612,877 458.9%   
Current liabilities Rs m40,0187,245 552.3%   
Net working cap to sales %25.032.0 78.0%  
Current ratio x1.51.8 83.1%  
Inventory Days Days75111 67.6%  
Debtors Days Days119124 96.2%  
Net fixed assets Rs m39,0757,506 520.6%   
Share capital Rs m28282 345.7%   
"Free" reserves Rs m30,2810-   
Net worth Rs m42,70313,799 309.5%   
Long term debt Rs m24,8734,849 512.9%   
Total assets Rs m111,02626,068 425.9%  
Interest coverage x6.6-7.7 -85.6%   
Debt to equity ratio x0.60.4 165.7%  
Sales to assets ratio x0.70.7 101.9%   
Return on assets %7.9-15.2 -52.3%  
Return on equity %16.4-32.1 -51.2%  
Return on capital %17.5-19.8 -88.4%  
Exports to sales %43.30-   
Imports to sales %7.40-   
Net fx Rs m-24,1220-   
CASH FLOW
From Operations Rs m3,4491,501 229.8%  
From Investments Rs m-8,802-461 1,910.2%  
From Financial Activity Rs m6,9864,401 158.7%  
Net Cashflow Rs m9345,441 17.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.83 Rs / ZAR

Compare GLENMARK PHARMA With: ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare GLENMARK PHARMA With: DIVIS LABORATORIES  ALEMBIC PHARMA  VENUS REMEDIES  CIPLA  SANOFI INDIA  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views On News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - PFIZER COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS